The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). (Q40253730)

18 September 2017

1 reference

title

The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). (English)

1 reference

18 September 2017

1 reference

ChEBI release 2020-05-28

Weiss RB

1

1 reference

18 September 2017

Issell BF

series ordinal

2

1 reference

18 September 2017

publication date

1 December 1982

1 reference

18 September 2017

published in

Cancer Treatment Reviews

1 reference

18 September 2017

volume

9

1 reference

18 September 2017

issue

4

1 reference

18 September 2017

page(s)

313-330

1 reference

Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Combination therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

BCNU and X-ray therapy of intracerebral 9L rat tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Treatment of bronchogenic carcinoma. II. Small cell

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyU-l-nitrosourea (BCNU) in man and animals

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Mallory-Weiss lesion following cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma—Final evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

1,3-Bis (2-chloroethyl)-1-nitrosourea: Effects on advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Acute myelocytic leukemia following prolonged streptozotocin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Combination chemotherapy of advanced lung cancer.A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

BCNU (1,3), BIS(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Visual abnormalities following nitrosourea treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma and reticulum cell sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Optic neuroretinitis in association with BCNU and procarbazine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Clinical management of advanced gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

A comparative study of a bcnu containing 4-drug program versus mopp versus 3-drug combinations in advanced Hodgkin's disease.A cooperative study by the cancer and leukemia group B

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Phase I study of GANU and MCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Treatment of metastatic Ewing's sarcoma with BCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Controlled study of CCNU and radiation therapy in malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Experimental and clinical effect of ACNU in Japan, with emphasis on small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Nephrotoxicity of nitrosoureas

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Abuse of anticholinergic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Trial of 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in Advanced Bronchogenic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: low response rate in a Cooperative Group Study. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Small-Cell Carcinoma of the Lung: Therapeutic Management

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Hypersensitivity reactions to cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

The renal toxicity of cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

The nitrosoureas and pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Response of a rat brain tumor to fractionated therapy with low doses of BCNU and irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Cancer Treatment Needs Better Antiemetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

THEOPHYLLINE-INDUCED LOMUSTINE TOXICITY

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2882%2980043-1

7 January 2021

10.1016/S0305-7372(82)80043-1

Identifiers

DOI

1 reference

18 September 2017

1 reference